Aspira Women’s Health, a diagnostic company, has seen a surge in its shares following the announcement of a material transfer agreement with The University of Oxford. The agreement will allow Aspira to procure serum samples for the purpose of verifying and validating their endometriosis blood test algorithms.
Promising Market Response
As a result of this news, Aspira Women’s Health shares saw a 10% increase, reaching $4.39. This positive response comes as a welcome change for the company, which had previously experienced a significant dip, with its stock hitting a 52-week low of $2.31 on July 27. Over the past year, Aspira’s shares have seen a decline of 43%.
A Step Towards Enhanced Patient Care
The serum samples obtained through the agreement with The University of Oxford will play a crucial role in supporting the launch of Aspira’s innovative product, EndoCheck. Set to be released by the end of 2023, EndoCheck aims to provide clinicians with a powerful tool for assessing whether a patient’s chronic pain is caused by endometriosis, all without resorting to invasive procedures.
Advancing Diagnostic Capabilities
EndoCheck is a non-invasive blood test currently under development. It will be utilized alongside other non-surgical methods to aid in the diagnosis of endometriosis. By offering a non-invasive solution with a sensitivity and specificity comparable to invasive techniques like surgical biopsy and visualization, EndoCheck aims to address the needs of a large patient population.
